Tango Therapeutics Stock Performance
| TNGX Stock | USD 6.75 0.13 1.89% |
Tango Therapeutics holds a performance score of 22 on a scale of zero to a hundred. The entity has a beta of 4.17, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Tango Therapeutics will likely underperform. Use Tango Therapeutics potential upside, as well as the relationship between the accumulation distribution and period momentum indicator , to analyze future returns on Tango Therapeutics.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Tango Therapeutics are ranked lower than 22 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak technical and fundamental indicators, Tango Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (1.89) | Five Day Return (3.30) | Year To Date Return 115.65 | Ten Year Return (34.02) | All Time Return (34.02) |
1 | TNGX Reports Q1 Revenue Miss, Advances Cancer Treatments TNGX Stock News | 05/12/2025 |
2 | Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 12 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors | 05/21/2025 |
3 | Disposition of 9778 shares by Weber Barbara of Tango Therapeutics at 2.988 subject to Rule 16b-3 | 05/23/2025 |
4 | Tango Therapeutics to Participate in the 46th AnnualGoldman SachsGlobal Healthcare Conference | 05/27/2025 |
5 | Acquisition by Peters Malte of 37500 shares of Tango Therapeutics at 7.41 subject to Rule 16b-3 | 06/04/2025 |
6 | Acquisition by Borisy Alexis of 6250 shares of Tango Therapeutics subject to Rule 16b-3 | 06/05/2025 |
7 | Tango Therapeutics Approves Key Proposals at Annual Meeting - TipRanks | 06/06/2025 |
8 | Tango Therapeutics Moves 7.5 percent Higher Will This Strength Last | 06/23/2025 |
9 | Tango Therapeutics Announces First Patient Dosed in Phase 12 Trial of TNG462 plus Revolution ... | 06/27/2025 |
10 | Tango Therapeutics, Inc. added to Russell 3000 Value Index - MarketScreener | 06/30/2025 |
11 | Acquisition by Peters Malte of 6250 shares of Tango Therapeutics subject to Rule 16b-3 | 07/11/2025 |
12 | Does Tango Therapeutics Have the Potential to Rally 75.89 percent as Wall Street Analysts Expect | 07/14/2025 |
13 | Tango Therapeutics to Report Second Quarter 2025Financial Resul | 07/22/2025 |
14 | Will Tango Therapeutics Inc. stock benefit from AI tech trends - Superior capital gains - jammulinksnews.com | 07/24/2025 |
| Begin Period Cash Flow | 69.8 M | |
| Total Cashflows From Investing Activities | 86.1 M |
Tango Therapeutics Relative Risk vs. Return Landscape
If you would invest 149.00 in Tango Therapeutics on April 26, 2025 and sell it today you would earn a total of 526.00 from holding Tango Therapeutics or generate 353.02% return on investment over 90 days. Tango Therapeutics is currently generating 2.9448% in daily expected returns and assumes 10.1374% risk (volatility on return distribution) over the 90 days horizon. In different words, 90% of stocks are less volatile than Tango, and 41% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Tango Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Tango Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Tango Therapeutics, and traders can use it to determine the average amount a Tango Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2905
| Best Portfolio | Best Equity | |||
| Good Returns | TNGX | |||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 10.14 actual daily | 90 90% of assets are less volatile |
Expected Return
| 2.94 actual daily | 59 59% of assets have lower returns |
Risk-Adjusted Return
| 0.29 actual daily | 22 78% of assets perform better |
Based on monthly moving average Tango Therapeutics is performing at about 22% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Tango Therapeutics by adding it to a well-diversified portfolio.
Tango Therapeutics Fundamentals Growth
Tango Stock prices reflect investors' perceptions of the future prospects and financial health of Tango Therapeutics, and Tango Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Tango Stock performance.
| Return On Equity | -0.61 | ||||
| Return On Asset | -0.27 | ||||
| Operating Margin | (7.89) % | ||||
| Current Valuation | 565.97 M | ||||
| Shares Outstanding | 108.39 M | ||||
| Price To Book | 4.47 X | ||||
| Price To Sales | 18.19 X | ||||
| Revenue | 42.07 M | ||||
| Gross Profit | (101.31 M) | ||||
| EBITDA | (143.1 M) | ||||
| Net Income | (130.3 M) | ||||
| Cash And Equivalents | 416.36 M | ||||
| Cash Per Share | 4.73 X | ||||
| Total Debt | 36.49 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 9.76 X | ||||
| Book Value Per Share | 1.54 X | ||||
| Cash Flow From Operations | (131.5 M) | ||||
| Earnings Per Share | (1.20) X | ||||
| Market Capitalization | 745.75 M | ||||
| Total Asset | 316.49 M | ||||
| Retained Earnings | (501.56 M) | ||||
| Working Capital | 228.17 M | ||||
About Tango Therapeutics Performance
Evaluating Tango Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Tango Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Tango Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 59.09 | 86.15 | |
| Return On Tangible Assets | (0.41) | (0.43) | |
| Return On Capital Employed | (0.52) | (0.55) | |
| Return On Assets | (0.41) | (0.43) | |
| Return On Equity | (0.65) | (0.69) |
Things to note about Tango Therapeutics performance evaluation
Checking the ongoing alerts about Tango Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Tango Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Tango Therapeutics is way too risky over 90 days horizon | |
| Tango Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 42.07 M. Net Loss for the year was (130.3 M) with loss before overhead, payroll, taxes, and interest of (101.31 M). | |
| Tango Therapeutics currently holds about 416.36 M in cash with (131.5 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.73. | |
| Over 97.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Will Tango Therapeutics Inc. stock benefit from AI tech trends - Superior capital gains - jammulinksnews.com |
- Analyzing Tango Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Tango Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Tango Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Tango Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Tango Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Tango Therapeutics' stock. These opinions can provide insight into Tango Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Tango Stock Analysis
When running Tango Therapeutics' price analysis, check to measure Tango Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tango Therapeutics is operating at the current time. Most of Tango Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tango Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tango Therapeutics' price. Additionally, you may evaluate how the addition of Tango Therapeutics to your portfolios can decrease your overall portfolio volatility.